MT 4561
Alternative Names: MT-4561Latest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antineoplastics
- Mechanism of Action Bromodomain containing protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 23 Oct 2024 Preclinical trials in Acute myeloid leukaemia in Japan (unspecified route), prior to October 2024
- 23 Oct 2024 Pharmacodynamics data from preclinical trials in Acute myeloid leukaemia presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)